12:00 AM
 | 
Jan 02, 2012
 |  BC Week In Review  |  Company News  |  Deals

Compugen deal

Compugen will receive $8 million in R&D funding from investment firm Baize Investments Ltd. to support Compugen's Pipeline Program, which consists of more than 30 mAbs and proteins for cancer and autoimmune indications. In exchange for the investment, Baize receives a stake...

Read the full 196 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >